Search
Close this search box.

The clinical impact of glycobiology: targeting selectins, Siglecs and mammalian glycans

Advances in genomics, glycoproteomics and tools from chemical biology have made glycobiology more tractable and understandable. Dysregulated glycosylation plays a major role in disease processes from immune evasion to cognition, sparking research that aims to target glycans for therapeutic benefit. The field is ready for a boom in drug development. Glycobiology has already produced several drugs that have improved human health or are currently being translated to the clinic.
pselectin.png
The review by B.A.H. Smith & C.R. Bertozzi, focuses on three areas — selections, Siglecs and glycan- targeted antibodies. It aims to tell the stories behind therapies inspired by glycans and to outline how the lessons learned from these approaches are paving the way for future glycobiology-focused therapeutics. Of significant interest is the timeline of key developments in translational glycobiology, and the recent successes reached over the last decade.
modality_of_siglet_therapy.png

Reference Benjamin A. H. Smith & Carolyn R. Bertozzi,
Nature Reviews | Drug Discovery, https://doi.org/10.1038/s41573-020-00093-1
timeline.png

Latest news

The Kuiper Belt object (KBO) Arrokoth orbits the Sun as part of the Kuiper belt...

The role of glycosaminoglycans (GAGs) in modulating bone morphogenetic protein (BMP) signaling is a relatively...

Glycans, due to their variable compositions and highly dynamic conformations, significantly enhance the diversity of...

Advances in simulation, combined with technological developments in high-performance computing, have made it possible to...